Sarah Jackson1, Ana Creo1, Seema Kumar2. 1. Division of Pediatric Endocrinology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. 2. Division of Pediatric Endocrinology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. kumar.seema@mayo.edu.
Abstract
PURPOSE OF REVIEW: Cardiovascular disease is the leading cause of death in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). Subclinical atherosclerotic changes are noted in youth with diabetes; therefore, timely identification and management of modifiable cardiovascular risk factors including hyperlipidemia is crucial. We review the current guidelines for hyperlipidemia screening and treatment in youth with T1D and T2D. We discuss the efficacy of non-pharmacological strategies including dietary modifications, exercise, and glycemic control and pharmacological therapy. We summarize reported rates of treatment of diabetes-related hyperlipidemia in youth. RECENT FINDINGS: Hyperlipidemia is prevalent among youth with T1D and T2D. Vast majority of youth with diabetes-related hyperlipidemia do not receive lipid-lowering treatments. There are several factors that contribute to suboptimal management of hyperlipidemia in youth with diabetes including limited data on efficacy and safety of statins in youth with diabetes. We propose strategies to improve hyperlipidemia management including education of providers and patients, quality improvement methods, and electronic health record alerts. Additionally, further studies are warranted to examine the safety of statins in youth with diabetes, cost-benefit analysis to aggressive screening and treatment, and long-term effect for improving cardiovascular morbidity and mortality.
PURPOSE OF REVIEW: Cardiovascular disease is the leading cause of death in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). Subclinical atherosclerotic changes are noted in youth with diabetes; therefore, timely identification and management of modifiable cardiovascular risk factors including hyperlipidemia is crucial. We review the current guidelines for hyperlipidemia screening and treatment in youth with T1D and T2D. We discuss the efficacy of non-pharmacological strategies including dietary modifications, exercise, and glycemic control and pharmacological therapy. We summarize reported rates of treatment of diabetes-related hyperlipidemia in youth. RECENT FINDINGS: Hyperlipidemia is prevalent among youth with T1D and T2D. Vast majority of youth with diabetes-related hyperlipidemia do not receive lipid-lowering treatments. There are several factors that contribute to suboptimal management of hyperlipidemia in youth with diabetes including limited data on efficacy and safety of statins in youth with diabetes. We propose strategies to improve hyperlipidemia management including education of providers and patients, quality improvement methods, and electronic health record alerts. Additionally, further studies are warranted to examine the safety of statins in youth with diabetes, cost-benefit analysis to aggressive screening and treatment, and long-term effect for improving cardiovascular morbidity and mortality.
Authors: Elaine M Urbina; Thomas R Kimball; Philip R Khoury; Stephen R Daniels; Lawrence M Dolan Journal: J Hypertens Date: 2010-08 Impact factor: 4.844
Authors: Emelia J Benjamin; Salim S Virani; Clifton W Callaway; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Stephanie E Chiuve; Mary Cushman; Francesca N Delling; Rajat Deo; Sarah D de Ferranti; Jane F Ferguson; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Pamela L Lutsey; Jason S Mackey; David B Matchar; Kunihiro Matsushita; Michael E Mussolino; Khurram Nasir; Martin O'Flaherty; Latha P Palaniappan; Ambarish Pandey; Dilip K Pandey; Mathew J Reeves; Matthew D Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Uchechukwu K A Sampson; Gary M Satou; Svati H Shah; Nicole L Spartano; David L Tirschwell; Connie W Tsao; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2018-01-31 Impact factor: 29.690
Authors: Shona J Livingstone; Daniel Levin; Helen C Looker; Robert S Lindsay; Sarah H Wild; Nicola Joss; Graham Leese; Peter Leslie; Rory J McCrimmon; Wendy Metcalfe; John A McKnight; Andrew D Morris; Donald W M Pearson; John R Petrie; Sam Philip; Naveed A Sattar; Jamie P Traynor; Helen M Colhoun Journal: JAMA Date: 2015-01-06 Impact factor: 56.272
Authors: Jean M Lawrence; Jasmin Divers; Scott Isom; Sharon Saydah; Giuseppina Imperatore; Catherine Pihoker; Santica M Marcovina; Elizabeth J Mayer-Davis; Richard F Hamman; Lawrence Dolan; Dana Dabelea; David J Pettitt; Angela D Liese Journal: JAMA Date: 2021-08-24 Impact factor: 157.335
Authors: Amy S Shah; R Paul Wadwa; Dana Dabelea; Richard F Hamman; Ralph D'Agostino; Santica Marcovina; Stephen R Daniels; Lawrence M Dolan; Nora F Fino; Elaine M Urbina Journal: Pediatr Diabetes Date: 2015-04-24 Impact factor: 4.866
Authors: Timothy S Church; Angela M Thompson; Peter T Katzmarzyk; Xuemei Sui; Neil Johannsen; Conrad P Earnest; Steven N Blair Journal: Diabetes Care Date: 2009-04-14 Impact factor: 19.112
Authors: Jasmin Divers; Elizabeth J Mayer-Davis; Jean M Lawrence; Scott Isom; Dana Dabelea; Lawrence Dolan; Giuseppina Imperatore; Santica Marcovina; David J Pettitt; Catherine Pihoker; Richard F Hamman; Sharon Saydah; Lynne E Wagenknecht Journal: MMWR Morb Mortal Wkly Rep Date: 2020-02-14 Impact factor: 35.301